Aegis Surgical Ltd.

Aim Achieving adequate hemostasis is a critical aspect of surgical practice, especially in orthopedics, where bleeding can impact visibility and patient outcomes. Surgi-ORC® (Aegis Lifesciences Pvt. Ltd., Ahmedabad, India), an oxidized regenerated cellulose hemostatic agent, was evaluated for its safety, efficacy, biocompatibility, and clinical performance in real-world patients undergoing orthopedic surgeries. Method This prospective observational study included patients undergoing upper limb, lower limb, or axial skeletal orthopedic surgeries. Blood loss, time to hemostasis (TTH), and surgeon-rated performance parameters such as ease of application, conformation to tissue, and preparation were recorded to assess the performance of Surgi-ORC® at predefined time points. Biocompatibility assessments were conducted through in vitro and in vivo tests, including reactivity, sensitization, systemic toxicity, tissue response, and hemolytic potential. Results The study involved 59 patients undergoing orthopedic surgeries using Surgi-ORC® variants: Powder (n=4), Knit (n=5), Original/Standard (n=4), Fibril (n=42), and Non-Woven/Snow (n=4). Hemostasis was achieved in 100% of cases within ≤ five minutes, with a mean TTH of 1.95 minutes (Surgi-ORC® Original/Standard). Powder demonstrated the lowest mean TTH across all surgeries, averaging 0.83 to 1.08 minutes. Surgeon feedback highlighted excellent handling, ease of application, and conformance to tissue without sticking/adherence to surgical gloves/surgical instruments. No infections, adverse events, or complications occurred over 60 days, and all patients showed stable recoveries. The surgeon confirmed complete absorption by day two.  Conclusion Surgi-ORC® is a reliable and effective hemostatic agent for orthopedic surgeries. Its ease of use, handling characteristics, ease of placing, stability upon placement, and safety profile make it a preferred choice among surgeons.

The continued sustained progress of antibiotic-resistant microorganisms and nosocomial pathogens creates a critical problem for patients undergoing surgical procedures and specifically at post-operative surgical sites.In the event of post-operative infections caused by these microorganism, treatment and recovery for the patient becomes problematic.Hemostats are effective in control of bleeding with different mechanisms of action at various surgical sites.Oxidized Regenerated Cellulose (ORC) is an effective passive haemostat and has a proven antibacterial activity attributed to its low pH.The present study reports the invitro antibacterial activity of a com. brand of ORC (Surgi ORC, Aegis Lifesciences, India) on antibiotic resistance and nosocomial pathogens.Thirty-one microorganisms of ATCC strains were studied by microbial challenge test on recovery plates on four variants of Surgi ORC.All the variants showed significant antibacterial activity on six of seven strains of antibiotic and Multi Drug Resistance (MDR) microbes.Surgi ORC presented mild activity only on MDR Clostridium difficile.Of the 24 non- antibiotic resistant and other pathogens tested, Surgi ORC showed extremely significant microbial activity in 13 strains (P<0.001), very significant and moderate activity in 7 strains (P<0.01) and mild activity in only 4 strains of microorganisms (P<0.05).The broad-spectrum antibacterial property even in antibiotic resistant and nosocomial pathogens of Surgi ORC is with reference to the intrinsic characteristics of oxidized cellulose, due to its low pH (3.0 to 4.0).Since low pH affects a relatively broad spectrum of bacteria and does not act in a mechanism-specific manner, as do antibiotics.

A review.Hemorrhage control is a critical aspect of medical interventions and surgical procedures.Various hemostatic agents, such as gelatin powder and polysaccharide powder, have been developed to facilitate effective blood clotting and minimize bleeding.Gelatin powder, derived from animal sources, is a widely used hemostat due to its biocompatibility and availability.The major advantages of gelatin powder include its ability to form a stable clot, its adhesiveness to tissues, and its ease of application.Gelatin acts by promoting platelet aggregation and accelerating the coagulation cascade, thereby facilitating hemostasis.Moreover, gelatin is generally well-tolerated by patients, with minimal allergic reactions reported.Polysaccharides possess unique properties, including biodegradability, biocompatibility, and their ability to promote blood clotting through the activation of the coagulation pathway.These powders can absorb water, forming a gel-like substance that aids in clot formation.Addnl., polysaccharides often have antimicrobial properties, reducing the risk of infection at the wound site.However, the disadvantages of polysaccharide powders as hemostats include their potential immunogenicity, the need for precise dosage control, and the possibility of delayed clotting due to variations in individual responses.The choice of hemostatic agent should be based on the specific clin. context, patient characteristics, and the overall risk-benefit anal.